ArticleCell death & disease2014
Serum-dependent processing of late apoptotic cells for enhanced efferocytosis.
Article in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Parabacteroides goldsteinii and its metabolite 7-KLCA attenuate endometriosis via TGR5 to reprogram macrophages by modulating the PPARγ/GPR132 axis.NPJ biofilms and microbiomes · 2026Article
- Glucocorticoids induce a phagocytic C1Q+ macrophage phenotype primed for IFNγ-dependent CXCL9 secretion.Scientific reports · 2026Article
- Article
- epHero - a tandem-fluorescent probe to track the fate of apoptotic cells during efferocytosis.Cell death discovery · 2024Article
- Conserved and Distinct Elements of Phagocytosis in Human andInternational journal of molecular sciences · 2021Review
- Scorpion Venom Peptide Effects on Inhibiting Proliferation and Inducing Apoptosis in Canine Mammary Gland Tumor Cell Lines.Animals : an open access journal from MDPI · 2021Article
- Phagocytic clearance of apoptotic, necrotic, necroptotic and pyroptotic cells.Biochemical Society transactions · 2021Review
- Phagocytosis of Necrotic Debris at Sites of Injury and Inflammation.Frontiers in immunology · 2019Review
- Efferocytosis and autoimmune disease.International immunology · 2018Review
- Impaired efferocytosis by monocytes in multiple myeloma.Oncology letters · 2018Article
- The immune response to secondary necrotic cells.Apoptosis : an international journal on programmed cell death · 2017Review
- Article
- Extracellular histones, cell-free DNA, or nucleosomes: differences in immunostimulation.Cell death & disease · 2016Review
- Uncoupling complement C1s activation from C1q binding in apoptotic cell phagocytosis and immunosuppressive capacity.Clinical immunology (Orlando, Fla.) · 2016Article
- A subset of patients with systemic lupus erythematosus fails to degrade DNA from multiple clinically relevant sources.Arthritis research & therapy · 2015Article
- Contribution of Defective PS Recognition and Efferocytosis to Chronic Inflammation and Autoimmunity.Frontiers in immunology · 2014Review
- Clearance of Apoptotic Bodies, NETs, and Biofilm DNA: Implications for Autoimmunity.Frontiers in immunology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Binding of the serum protein complement component C1q to the surface of dying cells facilitates their clearance by phagocytes in a process termed efferocytosis. Here, we investigate during which phase of apoptotic cell death progression C1q binding takes place. Purified C1q was found to bind to all dying cells and, albeit weaker, also to viable cells. The presence of serum abrogated completely the binding to viable cells. In addition, C1q binding to dying cells was limited to a specific subpopulation of late apoptotic/secondary necrotic cells. Co-culturing serum-treated apoptotic cells with human monocytes revealed a much higher phagocytosis of C1q-positive than of C1q-negative late apoptotic/secondary necrotic cells. But this phagocytosis-promoting activity could not be observed with purified C1q. Serum-treated C1q-positive late apoptotic/secondary necrotic cells exhibited a similar volume, a similar degraded protein composition, but a much lower DNA content in comparison with the remaining late apoptotic/secondary necrotic cells. This was mediated by a serum-bound nuclease activity that could be abrogated by G-actin, which is a specific inhibitor of serum DNase I. These results show that serum factors are involved in the prevention of C1q binding to viable cells and in the processing of late apoptotic/secondary necrotic cells promoting cell death progression toward apoptotic bodies. This process leads to the exposure of C1q-binding structures and facilitates efferocytosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.